• Contact Us
  • News
Dermira Eli Lilly Logo
  • Company
    • About Us
    • Leadership
    • Medical Information
    • Contact Us
  • Our Focus
    • Overview
    • Hyperhidrosis
    • Atopic Dermatitis
    • Helpful Resources
    • Grants & Sponsorships
  • Our Medicines
    • QBREXZA® (glycopyrronium) cloth
    • Authorized Distributors
    • Suppliers
  • R&D
    • Pipeline
    • Lebrikizumab
    • Clinical Trials
    • Early Research Program
    • Medical Information
  • Careers
    • Culture & Values
    • Job Openings
  • Media
    • News Releases
MENU MENU
mobile logo mobile
close-btn
  • Company
    • About Us
    • Leadership
    • Medical Information
    • Contact Us
  • Our Focus
    • Overview
    • Hyperhidrosis
    • Atopic Dermatitis
    • Helpful Resources
    • Grants & Sponsorships
  • Our Medicines
    • QBREXZA® (glycopyrronium) cloth
    • Authorized Distributors
    • Suppliers
  • R&D
    • Pipeline
    • Lebrikizumab
    • Clinical Trials
    • Early Research Program
    • Medical Information
  • Careers
    • Culture & Values
    • Job Openings
  • Media
    • News Releases
  • Contact Us
  • News
FOLLOW US
borderborder

Realize the potential within

LEARN MORE

Our Focus

HYPERHIDROSIS

Sweating beyond what is physiologically necessary—a condition affecting millions in the U.S. with few safe, effective treatments

Atopic Dermatitis

A chronic skin condition that leads to severe, persistent itching, affecting millions in the U.S.

Careers

border

We are enthusiastic about the work we do and our culture. If you are an energetic self-starter who wants to join a great team and make a difference in the lives of patients, we may have a role for you.

Join Our Team

Our Medicines

border

The first medication from Dermira is designed to address the unmet needs of patients.

See More

Recent News

  • 01/10/2020
    Lilly Announces Agreement to Acquire Dermira
  • 12/10/2019
    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 12/10/2019
    Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis
  • 11/27/2019
    Dermira to Participate in December Investor Conferences
  • 11/14/2019
    Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference
View All News

Company

  • About Us
  • Leadership
  • Medical Information
  • Contact Us

Our Focus

  • Overview
  • Hyperhidrosis
  • Atopic Dermatitis
  • Helpful Resources
  • Grants & Sponsorships

OUR MEDICINES

  • QBREXZA® (glycopyrronium) cloth
  • Authorized Distributors
  • Suppliers

R&D

  • Pipeline
  • Lebrikizumab
  • Clinical Trials
  • Early Research Program
  • Medical Information

CAREERS

  • Culture & Values
  • Job Openings

MEDIA

  • News Releases
FOLLOW US
borderborder
  • Corporate Compliance
  • Privacy Policy
  • Terms of Use
Dermira Eli Lilly Logo
  • Corporate Compliance
  • Privacy Policy
  • Terms of Use
  • Contact Us
  • News
FOLLOW US
borderborder
Dermira Eli Lilly Logo
  • Corporate Compliance
  • Privacy Policy
  • Terms of Use
© 2021 Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. All rights reserved. Dermira and Qbrexza are trademarks of Dermira, Inc.
NP-US-GPT-0061 06/2018

You Are Now Leaving Dermira.com

You’ve clicked on a link for a third-party site, which Dermira, Inc., a wholly-owned subsidiary of Eli Lilly & Company, does not control, influence, or endorse. Dermira is not responsible for any content on this third-party site, including the privacy policy. Click “Continue” to leave or “Return” to return to Dermira.com.

RETURN
CONTINUE
NP-US-GPT-0061 06/2018